FDA accepts Teva’s NDA for SD-809 to treat Huntington disease
HD is caused by the progressive breakdown of nerve cells in the brain that affects about five to seven people per 100,000 in western countries, according to the
ProBio has entered into an exclusive worldwide licensing agreement with South Korean biotechnology firm AbTis to develop and commercialise an early-stage therapeutic antibody asset.
"Immuno-oncology has emerged as a particularly promising field to create potentially curative treatment options for many cancer patients," said Victoria Richon, Vice-President and Head of Cancer Research, Discovery
Both the firms will collaborate on seeking regulatory approval from Australia’s Therapeutic Goods Administration (TGA) and New Zealand’s Medicines and Medical Devices Safety Authority (Medsafe). As part of